melanoma patients who discontinued nivolumab and ipilimumab experienced equal or better pfs
Published 7 years ago • 834 plays • Length 3:16Download video MP4
Download video MP3
Similar videos
-
2:54
combining nivolumab and ipilimumab in patients with resected stage iv melanoma
-
2:04
benefits and risks of reinduction ipilimumab/nivolumab in patients with melanoma
-
2:14
immuned: adjuvant nivolumab and ipilimumab increases os in stage iv melanoma
-
0:37
tils prolong pfs compared with pembrolizumab in advanced melanoma
-
3:59
checkmate 067 - combined nivolumab and ipilimumab
-
6:16
treatment-free survival results of nivolumab and salvage nivolumab ipilimumab for accrcc
-
2:11
dr. long on rationale for nivolumab/ipilimumab in patients with melanoma who have brain mets
-
6:45
asco 2015: combined nivolumab and ipilimumab or monotherapy shown promise in untreated melanoma
-
7:13
progression patterns in post-ipilimumab and anti-pd-1 in metastatic melanoma
-
6:21
new long-term data 'clearly favor' combination ipilimumab/nivolumab in melanoma
-
2:48
checkmate067 outcomes: nivolumab plus ipilimumab in advanced melanoma
-
7:19
nivolumab alone or combined with ipilimumab vs ipi alone in advanced melanoma
-
5:44
hcrn-gu16-260: nivolumab and salvage nivolumab-ipilimumab in patients with advanced rcc
-
5:39
nivolumab plus ipilimumab in advanced melanoma
-
7:34
adjuvant therapy for melanoma: nivolumab, pembrolizumab, ipilimumab, dabrafenib and trametinib
-
2:10
dr. weber on the toxicity profile of nivolumab versus ipilimumab for melanoma
-
1:56
checkmate 067: combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
6:12
nivolumab vs ipilimumab for high risk melanoma patients
-
2:37
comment: nivolumab-based treatment halts melanoma progression